Studies show that SYK is involved in the signaling pathways that drive AML [4,8,9,10,11,12,13,14,15,16], and the cascade of FMS-related tyrosine kinase 3 (FLT3) signaling are of special interest since approximately 1/3 of AML patients have a mutation in the FLT3 gene [7]. This evidence concerns the gene FLT3 and acute myeloid leukemia.